SML2881
R-VK4-40
≥98% (HPLC)
别名:
R-VK4-40, N-[(3R)-4-[4-(2-Chloro-3-ethylphenyl)-1-piperazinyl]-3-hydroxybutyl]-1H-indole-2-carboxamide
InChI
1S/C25H31ClN4O2/c1-2-18-7-5-9-23(24(18)26)30-14-12-29(13-15-30)17-20(31)10-11-27-25(32)22-16-19-6-3-4-8-21(19)28-22/h3-9,16,20,28,31H,2,10-15,17H2,1H3,(H,27,32)/t20-/m1/s1
InChI key
OIRZLTZLOKARTG-HXUWFJFHSA-N
SMILES string
O=C(C1=CC2=C(C=CC=C2)N1)NCC[C@H](CN3CCN(C4=CC=CC(CC)=C4Cl)CC3)O
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
Quality Level
Biochem/physiol Actions
R-VK4-40 is an orally available, highly selective and potent dopamine D3 receptor (D3R) antagonists that does not exhibit unwanted cardiovascular effects. R-VK4-40 attenuates oxycodone induced rewards without compromising antinociceptive effects in rats. It reduces oxycodone self-administration and suppress naloxone-caused opioid withdrawal.
orally available, highly selective and potent dopamine D3 receptor (D3R) antagonists that does not exhibit unwanted cardiovascular effects
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Anver Basha Shaik et al.
Journal of medicinal chemistry, 62(20), 9061-9077 (2019-09-19)
Dopamine D3 receptors (D3R) play a critical role in neuropsychiatric conditions including substance use disorders (SUD). Recently, we reported a series of N-(3-hydroxy-4-(4-phenylpiperazin-1-yl)butyl)-1H-indole-2-carboxamide analogues as high affinity and selective D3R lead molecules for the treatment of opioid use disorders (OUD).
Chloe J Jordan et al.
Neuropharmacology, 158, 107597-107597 (2019-04-12)
Prescription opioid abuse is a global crisis. New treatment strategies for pain and opioid use disorders are urgently required. We evaluated the effects of R-VK4-40, a highly selective dopamine (DA) D3 receptor (D3R) antagonist, on the rewarding and analgesic effects
Chloe J Jordan et al.
The Journal of pharmacology and experimental therapeutics, 371(3), 602-614 (2019-09-29)
Opioid and cocaine abuse are major public health burdens. Existing medications for opioid use disorder are limited by abuse liability and side effects, whereas no treatments are currently approved in the United States for cocaine use disorder. Dopamine D3 receptor
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持